Breakthroughs in Synovial Sarcoma & Myxoid/Round Cell Liposarcoma
Notice bibliographique
Résumé
Synovial Sarcoma: Synovial SarcomaIn a stride forward in oncological therapeutics, the SPEARHEAD-1 Phase II trial (NCT04044768) has unveiled the significant potential of afamitresgene autoleucel (afami-cel) in treating patients with advanced synovial sarcoma and myxoid/round cell liposarcoma. The findings were published in The Lancet (2024; https://doi.org/10.1016/S0140-6736(24)00319-2). The international, open-label trial conducted across 23 distinguished medical centers in Canada, the U.S., and Europe has offered new hope to clinicians and patients grappling with these rare and aggressive mesenchymal malignancies. The impetus for this study arises from the notable outcomes observed in the earlier Phase I trial (NCT03132922) where afami-cel demonstrated acceptable safety profiles and showcased encouraging efficacy in treating advanced synovial sarcoma. Building upon this foundation, SPEARHEAD-1 aimed to delve deeper into the therapeutic potential of afami-cel, specifically for patients expressing HLA-A∗02 and MAGE-A4, which are pivotal markers in these malignancies characterized by limited treatment options. The trial enrolled a carefully selected cohort of heavily pretreated patients ages 16-75 years with metastatic or unresectable synovial sarcoma or myxoid/round cell liposarcoma. These individuals had already undergone at least one previous line of anthracycline-containing or ifosfamide-based chemotherapy, representing a population with few remaining treatment alternatives. The primary endpoint of interest in cohort 1, comprising 52 enrolled patients between December 17, 2019, and July 27, 2021, was the overall response rate. Key findings from the study include an overall response rate of 37 percent, with 39 percent of patients with synovial sarcoma and 25 percent of patients with myxoid/round cell liposarcoma showing positive responses to afami-cel. The median follow-up time was 32.6 months, providing valuable insights into the durability of these responses. One of the notable aspects of the study was the manageable safety profile of afami-cel. Cytokine release syndrome, a common side effect of immunotherapies, occurred in 71 percent of patients but was mostly mild (one Grade 3 event). The most common Grade 3 or worse adverse events were cytopenias, including lymphopenia (96%), neutropenia (85%), and leukopenia (81%). Importantly, no treatment-related deaths were reported during the study period. Despite the trial's inherent limitations, such as its single-arm design and logistical intricacies, the outcomes provide a compelling rationale for further research and potential integration of afami-cel into the evolving treatment paradigm for these challenging sarcomas. Moreover, recruitment closed for cohorts 1 and 2 and is ongoing for cohort 3, signifying the enduring commitment to advancing therapeutic strategies for patients grappling with these complex and difficult-to-treat sarcomas. For additional insights, Oncology Times connected with lead author Sandra D'Angelo, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center specializing in the treatment of soft tissue sarcomas, bone sarcomas, and Merkel cell carcinoma. Oncology Times: What factors were associated with higher response rates in patients with synovial sarcoma treated with afami-cel? D'Angelo: “Factors found to be associated with higher response include female gender, higher MAGE-A4 expression, lower disease burden, and lack of bridging therapy.” Oncology Times: What were the most common Grade 3 or worse adverse events observed in patients treated with afami-cel in the SPEARHEAD-1 trial and how were they managed? D'Angelo: “Cytopenias were the most common Grade 3 or worse adverse events. Lymphopenia occurred in 50 (96%) patients, neutropenia in 44 (85%), and leukopenia in 42 (81%). All resolved within 4 weeks with supportive measures. Cytokine release syndrome events were mostly Grade 1/2. Cytokine release syndrome was managed with supportive care and 19 (37%) patients received tocilizumab. Two of the 19 patients required corticosteroids and all cases resolved.” Oncology Times: Based on the results of the SPEARHEAD-1 trial, what are the potential implications for the use of afami-cel as a treatment option for refractory synovial sarcoma and myxoid/round cell liposarcoma expressing HLA-A∗02 and MAGE-A4? D'Angelo: “These findings support the use of afami-cel for patients with synovial sarcoma expressing HLA-A∗02 and MAGE-A4. The preference to utilize this therapy earlier in a patient's treatment journey is also supported with these data.” Dibash Kumar Das is a contributing writer.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction distillée sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.
Scores Codex et Gemma par catégorie
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,000 | 0,000 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,001 | 0,000 |
| Bibliométrie | 0,000 | 0,000 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,000 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,002 | 0,003 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; les deux têtes enseignantes s’accordent sur ce qui est montré ici.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».